FINWIRES · TerminalLIVE
FINWIRES

HKG:0874

9 stories mentioning HKG:0874Updated 31d ago

Every FINWIRES story that references HKG:0874, newest first.

What's the latest news on HKG:0874?

Asia

Guangzhou Baiyunshan Pharma's Profit Falls 17% in H1

Guangzhou Baiyunshan Pharmaceutical (HKG:0874, SHA:600332) posted an attributable net profit of 2.10 billion yuan for the first half of 2026, down 17% from 2.52 billion yuan a year earlier.Earnings per share rose to at 1.289 yuan from 1.548 yuan in the year-ago period, according to a Friday Hong Kong bourse filing.Revenue increased 0.61% year over year to 42.1 billion yuan from 41.8 billion yuan.The company proposed a cash dividend of 0.30 yuan per share, inclusive of tax, to all shareholders.

HKG:0874SHA:600332
Asia

Baiyunshan Pharmaceutical Subsidiary Gets China Supplementary Drug Nod for Brain Injury Injection

Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) subsidiary Guangzhou Baiyunshan Tianxin Pharmaceutical received supplementary drug application approval from China's National Medical Products Administration for its cytidine diphosphate choline sodium injection.The drug, also known as citicoline sodium, is indicated for acute traumatic brain injury and post-brain surgery-related conditions, according to a Thursday filing with the Shanghai bourse.

HKG:0874SHA:600332
Asia

Baiyunshan Pharmaceutical's Unit Gets Macao Drug Regulator's Nod for Cefazolin Sodium for Injection

Guangzhou Baiyunshan Pharmaceutical's (SHA:600332, HKG:0874) unit, Guangzhou Baiyunshan Tianxin Pharmaceutical, received drug registration certificates from Macao's pharmaceutical regulator for cefazolin sodium for injection, according to a Shanghai bourse filing on Tuesday.The drug is used to treat infections in the respiratory tract, urinary tract, skin and soft tissues, bones and other parts of the body.

HKG:0874SHA:600332
Asia

Baiyunshan Pharmaceutical Gets Nod to Trial New Indication for Zhangyanming Tablets

Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) received approval from China's ational Medical Products Administration to add a new functional indication for its clinical trial for Zhangyanming Tablets, according to a Shanghai bourse filing on Tuesday.The drug will be tested as a treatment for dry eye disease.

HKG:0874SHA:600332
Asia

Baiyunshan Pharmaceutical Subsidiary Receives Revised Drug Manufacturing License

Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) subsidiary Guangzhou Baiyunshan Zhongyi Pharmaceutical received an updated drug manufacturing license from the Guangdong Provincial Drug Administration in China, according to a Wednesday filing with the Shanghai bourse.The updated license covers the change of the person in charge of production, as well as the removal of a production facility.The changes will not affect Zhongyi Pharmaceutical's production.

HKG:0874SHA:600332
Asia

Baiyunshan Pharmaceutical Gets Macau Approval for Cefalexin Capsules

Guangzhou Baiyunshan Pharmaceutical Holdings (SHA:600332, HKG:0874) branch Baiyunshan Pharmaceutical Factory obtained a drug registration certificate from the Macau government for its cefalexin capsules, according to a Tuesday filing with the Shanghai bourse.The antibiotic is indicated for the treatment of respiratory tract, urinary tract, and skin and soft tissue infections.Cefalexin sales reached 24.7 million yuan in 2025, according to industry data cited in the filing. Baiyunshan's share was 4.5 million yuan.

HKG:0874SHA:600332
Asia

Baiyunshan Pharmaceutical Gains China's Nod for Influenza Antiviral Suspension

Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) branch entity, Baiyunshan Pharmaceutical General Factory, received drug registration from China's medical products regulator for oseltamivir phosphate for oral suspension.The drug treats influenza A and B, according to a Tuesday filing with the Shanghai bourse.

HKG:0874SHA:600332
Asia

Baiyunshan Pharmaceutical Gets Supplementary Approvals for Two Drugs

China's drug regulator granted Guangzhou Baiyunshan Pharmaceutical (SHA:600332, HKG:0874) a supplemental drug approval for its cefuroxime sodium injection and candesartan cilexetil tablets, according to a Tuesday filing with the Shanghai bourse.The approvals cover supplementary research.Cefuroxime sodium is indicated for acute respiratory, urinary tract, and other bacterial infections, whileCandesartan cilexetil is indicated for hypertension.

HKG:0874SHA:600332
Asia

Baiyunshan Pharmaceutical's Profit Falls 2% in Q1; Shanghai Shares Up 3%

Guangzhou Baiyunshan Pharmaceutical's (HKG:0874, SHA:600332) net profit attributable to shareholders fell 2.1% to 1.78 billion yuan in the first quarter, from 1.82 billion yuan a year earlier, according to a Monday Hong Kong bourse filing.Earnings per share came in at 1.097 yuan, compared with 1.120 yuan in the prior-year period.Income from operations rose 3.6% to 23.3 billion yuan from 22.5 billion yuan a year earlier.The pharmaceutical company's Hong Kong shares rose 2% during Tuesday morning's trade, while its Shanghai-listed shares were up 3%

HKG:0874SHA:600332

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:0874 in your portfolio
WheelAI
WheelAI
Analyze HKG:0874 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:0874